FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2016018338> ?p ?o ?g. }

• W2016018338 endingPage "1958" @default.
• W2016018338 startingPage "1945" @default.
• W2016018338 abstract "1. The cyclic AMP phosphodiesterases (PDE) expressed by CD4+ and CD8+ T-lymphocytes purified from the peripheral blood of normal adult subjects were identified and characterized, and their role in modulating proliferation and the biosynthesis of interleukin (IL)-2 and interferon (IFN)-gamma evaluated. 2. In lysates prepared from both subsets, SK&F 95654 (PDE3 inhibitor) and rolipram (PDE4 inhibitor) suppressed cyclic AMP hydrolysis indicating the presence of PDE3 and PDE4 isoenzymes in these cells. Differential centrifugation and subsequent inhibitor and kinetic studies revealed that the particulate fraction contained, predominantly, a PDE3 isoenzyme. In contrast, the soluble fraction contained a PDE4 (approximately 65% of total activity) and, in addition, a novel enzyme that had the kinetic characteristics of the recently identified PDE7. 3. Reverse transcription-polymerase chain reaction (RT-PCR) studies with primer pairs designed to recognise unique sequences in the human PDE4 and PDE7 genes amplified cDNA fragments that corresponded to the predicted sizes of HSPDE4A, HSPDE4B, HSPDE54D and HSPDE7. No message was detected for HSPDE4C after 35 cycles of amplification. 4. Functionally, rolipram inhibited phytohaemagglutinin- (PHA) and anti-CD3-induced proliferation of CD4+ and CD8+ T-lymphocytes, and the elaboration of IL-2, which was associated with a three to four fold increase in cyclic AMP mass. In all experiments, however, rolipram was approximately 60 fold more potent at suppressing IL-2 synthesis than at inhibiting mitogenesis. In contrast, SK&F 95654 failed to suppress proliferation and cytokine generation, and did not elevate the cyclic AMP content in T-cells. Although inactive alone, SK&F 95654 potentiated the ability of rolipram to suppress PHA- and anti-CD3-induced T-cell proliferation, and PHA-induced IL-2 release. 5. When a combination of phorbol myristate acetate (PMA) and ionomycin were used as a co-mitogen, rolipram did not affect proliferation but, paradoxically, suppressed IL-2 release indicating that cyclic AMP can inhibit mitogenesis by acting at, or proximal to, the level of inositol phospholipid hydrolysis. 6. Collectively, these data suggest that PDE3 and PDE4 isoenzymes regulate the cyclic AMP content, IL-2 biosynthesis and proliferation in human CD4+ and CD8+ T-lymphocytes. However, the ability of rolipram to suppress markedly mitogen-induced IL-2 generation without affecting T-cell proliferation suggests that growth and division of T-lymphocytes may be governed by mediators in addition to IL-2. Finally, T-cells have the potential to express PDE7, although elucidating the functional role of this enzyme must await the development of selective inhibitors." @default.
• W2016018338 created "2016-06-24" @default.
• W2016018338 creator A5014650317 @default.
• W2016018338 creator A5018753336 @default.
• W2016018338 creator A5030258071 @default.
• W2016018338 creator A5054872321 @default.
• W2016018338 creator A5068506060 @default.
• W2016018338 date "1996-08-01" @default.
• W2016018338 modified "2023-10-18" @default.
• W2016018338 title "Identification of cyclic AMP phosphodiesterases 3, 4 and 7 in human CD4+ and CD8+ T-lymphocytes: role in regulating proliferation and the biosynthesis of interleukin-2" @default.
• W2016018338 cites W1490734926 @default.
• W2016018338 cites W1491812285 @default.
• W2016018338 cites W1500824217 @default.
• W2016018338 cites W1510098440 @default.
• W2016018338 cites W1511652939 @default.
• W2016018338 cites W1519079218 @default.
• W2016018338 cites W1531393147 @default.
• W2016018338 cites W1533232725 @default.
• W2016018338 cites W1542652830 @default.
• W2016018338 cites W1563962170 @default.
• W2016018338 cites W1566399506 @default.
• W2016018338 cites W1570465948 @default.
• W2016018338 cites W1572273862 @default.
• W2016018338 cites W1574833807 @default.
• W2016018338 cites W1583794602 @default.
• W2016018338 cites W1605619919 @default.
• W2016018338 cites W1647832452 @default.
• W2016018338 cites W1650329927 @default.
• W2016018338 cites W1760775102 @default.
• W2016018338 cites W1796856428 @default.
• W2016018338 cites W1837479159 @default.
• W2016018338 cites W1891547652 @default.
• W2016018338 cites W1929551191 @default.
• W2016018338 cites W1963552993 @default.
• W2016018338 cites W1967494967 @default.
• W2016018338 cites W1987241389 @default.
• W2016018338 cites W1987412298 @default.
• W2016018338 cites W1988227673 @default.
• W2016018338 cites W1988620870 @default.
• W2016018338 cites W1992642548 @default.
• W2016018338 cites W2007458998 @default.
• W2016018338 cites W2010861152 @default.
• W2016018338 cites W2021137024 @default.
• W2016018338 cites W2023649056 @default.
• W2016018338 cites W2044045740 @default.
• W2016018338 cites W2047549229 @default.
• W2016018338 cites W2067861539 @default.
• W2016018338 cites W2071331983 @default.
• W2016018338 cites W2072199622 @default.
• W2016018338 cites W2079855969 @default.
• W2016018338 cites W2080294583 @default.
• W2016018338 cites W2083010777 @default.
• W2016018338 cites W2091903176 @default.
• W2016018338 cites W2092862861 @default.
• W2016018338 cites W2094342978 @default.
• W2016018338 cites W2101353664 @default.
• W2016018338 cites W2110362732 @default.
• W2016018338 cites W2130228041 @default.
• W2016018338 cites W2131230648 @default.
• W2016018338 cites W2134812217 @default.
• W2016018338 cites W2137796136 @default.
• W2016018338 cites W2151129289 @default.
• W2016018338 cites W2164508592 @default.
• W2016018338 cites W2168889062 @default.
• W2016018338 cites W2186507474 @default.
• W2016018338 cites W2411084688 @default.
• W2016018338 cites W2417906816 @default.
• W2016018338 cites W303857720 @default.
• W2016018338 cites W4254104742 @default.
• W2016018338 cites W4294216491 @default.
• W2016018338 cites W4301381893 @default.
• W2016018338 cites W87082738 @default.
• W2016018338 doi "https://doi.org/10.1111/j.1476-5381.1996.tb15629.x" @default.
• W2016018338 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/1909888" @default.
• W2016018338 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/8864528" @default.
• W2016018338 hasPublicationYear "1996" @default.
• W2016018338 type Work @default.
• W2016018338 sameAs 2016018338 @default.
• W2016018338 citedByCount "210" @default.
• W2016018338 countsByYear W20160183382012 @default.
• W2016018338 countsByYear W20160183382013 @default.
• W2016018338 countsByYear W20160183382014 @default.
• W2016018338 countsByYear W20160183382015 @default.
• W2016018338 countsByYear W20160183382016 @default.
• W2016018338 countsByYear W20160183382017 @default.
• W2016018338 countsByYear W20160183382018 @default.
• W2016018338 countsByYear W20160183382019 @default.
• W2016018338 countsByYear W20160183382020 @default.
• W2016018338 countsByYear W20160183382021 @default.
• W2016018338 countsByYear W20160183382022 @default.
• W2016018338 countsByYear W20160183382023 @default.
• W2016018338 crossrefType "journal-article" @default.
• W2016018338 hasAuthorship W2016018338A5014650317 @default.
• W2016018338 hasAuthorship W2016018338A5018753336 @default.
• W2016018338 hasAuthorship W2016018338A5030258071 @default.
• W2016018338 hasAuthorship W2016018338A5054872321 @default.
• W2016018338 hasAuthorship W2016018338A5068506060 @default.
• W2016018338 hasBestOaLocation W20160183381 @default.

• next